Bangalore, India, May 12, 2017 — Merck, a leading science and technology company, today announced the expansion of its M Lab™ Collaboration Center in Bangalore, India. The facility will provide biopharmaceutical manufacturers with a shared, exploratory environment where they can closely collaborate with Merck scientists and engineers to solve their toughest challenges and accelerate development of new therapies.
The expanded center, measuring 806 square meters, leverages Merck’s world-class technical and application expertise. It includes a simulated manufacturing environment and enables collaboration with Merck experts to evaluate processes and accelerates development and production of new therapies. In addition, education on best practices and new approaches to develop, optimize and scale-up processes and ways to simplify global technology transfer will be available to customers.
“Bangalore is a hub for India’s rapidly growing biopharmaceutical manufacturing industry,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “With the expansion of our M Lab™ Collaboration Center in Bangalore, we are providing customers with hands-on experience and customized support required to optimize their manufacturing processes to quickly bring much-needed therapies to patients.”
The new M Lab™ Collaboration Center in Bangalore is one of nine such centers around the world. Each center helps customers, government collaborators, academia, regulatory bodies and industry associations to increase their productivity, mitigate risk and improve processes with the help of an industry-leading team of Merck experts. Customers have access to sizing and simulation tools and methodologies, analytical and modelling support, training sessions and educational programs.
Click here to learn more about the M Lab™ Collaboration Centers and Merck’s new, expanded center in Bangalore.
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.